Ampio pharmaceuticals Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Ampio pharmaceuticals Contact Number

Contact Us Ampio Pharmaceuticals

5 hours ago Ampiopharma.com Show details

720 437 6500Contact Us; Home. Contact Us. Contact Us. Ampio Pharmaceuticals, Inc. 373 Inverness Parkway, Suite 200 Englewood, CO 80112 USA Main office: +1 720 437 6500.

Category: Contact SupportShow more

Ampio Pharmaceuticals

4 hours ago Ampiopharma.com Show details

Ampio Pharmaceuticals. Ampio Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for prevalent inflammatory conditions for which limited treatment options exist. We are advancing immunology-based therapies to provide safe and effective treatments for patients suffering from these diseases.

Category: Contact NumberShow more

Ampio Pharmaceuticals Crunchbase Company Profile & Funding

1 hours ago Crunchbase.com Show details

720-437-6500Contact Email [email protected] Phone Number 720-437-6500 Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs selected from its extensive portfolio with the potential to be safe and effective for improving patient care.

Founded: 2011
Founder: Michael Macaluso

Category: Contact NumberShow more

Ampio Pharmaceuticals, Inc. Company Profile Englewood

9 hours ago Dnb.com Show details

(720) 437-6500Find company research, competitor information, contact details & financial data for Ampio Pharmaceuticals, Inc. of Englewood, CO. Get the latest business insights from Dun & Bradstreet.

Employees: 17
Phone: (720) 437-6500
Location: 373 Inverness Pkwy Ste 200, Englewood, 80112-5898, CO

Category: Contact NumberShow more

About Us Ampio Pharmaceuticals

3 hours ago Ampiopharma.com Show details

About Ampio Pharmaceuticals. Ampio Pharmaceuticals is an innovative drug discovery and development company combining scientific, clinical, and manufacturing capabilities to develop novel immunology-based therapies aimed at treating prevalent inflammatory conditions for which limited treatment options exist.

Estimated Reading Time: 2 mins

Category: Contact NumberShow more

Ampio Pharmaceuticals Strengthens Management Team and

2 hours ago Ampiopharma.com Show details

610-731-1045About Ampio Pharmaceuticals. Media Contact. Katie Kennedy [email protected] 610-731-1045. Real Time Quote. SUBSCRIBE . Get email notifications of the latest Ampio news. Latest News . Ampio Pharmaceuticals Strengthens Management Team and Board of Directors October 13, 2021.

Category: Contact NumberShow more

Ampio Pharmaceuticals Inc (AMPE) LinkedIn

4 hours ago Linkedin.com Show details

Ampio Pharmaceuticals Inc (AMPE) 352 followers on LinkedIn. Ampio Pharmaceuticals Inc (AMPE) is a biotechnology company based out of Englewood, CO, United States.

Category: Contact NumberShow more

Ampio Pharmaceuticals, Inc. LinkedIn

4 hours ago Linkedin.com Show details

Ampio Pharmaceuticals, Inc. 222 followers on LinkedIn. Ampio Pharmaceuticals is a development stage biopharmaceutical company focused on the discovery and development of novel therapies aimed at

Category: Contact NumberShow more

Ampio Pharmaceuticals, Inc.: Rosen Law

2 hours ago Rosenlegal.com Show details

Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.-----Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Zachary Halper, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34 th Floor New York, NY

Category: Contact NumberShow more

Ampio Pharmaceuticals Details Early Positive Results for

Just Now Finance.yahoo.com Show details

Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of Ampion, our product candidate, to treat prevalent inflammatory conditions for

Category: Contact NumberShow more

FORM D SEC

4 hours ago Sec.gov Show details

516-487-1446Ampio Pharmaceuticals, Inc. Street Address 1 Street Address 2; 5445 DTC Parkway, P4: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; Greenwood Village: COLORADO: 80111: 516-487-1446

Category: Contact NumberShow more

AMPIO PHARMACEUTICALS, INC. sec.gov

1 hours ago Sec.gov Show details

125-12-3035On July 13, 2012, Ampio Pharmaceuticals, Inc. (“we”, “Ampio” or the “Company”) entered into an Amendment (“Amendment”) to the Underwriting Agreement (the “Underwriting Agreement”) dated July 12, 2012 with Aegis Capital Corp. (“Aegis”) and Fordham Financial Management, Inc. (“Fordham” and together with Aegis, the “underwriters”) and the Attorney-in-Fact for the

Category: Contact NumberShow more

Ampio Pharmaceuticals Reminds Stockholders to Vote Shares

1 hours ago Ampiopharma.com Show details

ENGLEWOOD, CO, August 12, 2021 – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, reminds stockholders to vote on the proposals listed in the Company’s proxy …

Category: Contact NumberShow more

AMPIO PHARMACEUTICALS, INC. : Shareholders Board Members

5 hours ago Marketscreener.com Show details

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and advancement of immunology-based therapies for prevalent inflammatory conditions. The Company's lead product candidate is Ampion, which contains a blood-derived cyclized peptide and small molecules that target multiple pathways in the innate immune response

Category: Contact NumberShow more

Ampio Pharmaceuticals, Inc. (AMPE) 10K Annual Reports

6 hours ago Last10k.com Show details

Inside Ampio Pharmaceuticals, Inc.'s 10-K Annual Report: Financial - Shares Highlight Our shelf registration statement, which was declared effective by the SEC in May 2020, provides us with the ability to sell up to an aggregate amount of $100.0 million of shares of common stock, preferred stock, debt securities, warrants and units, or any combination …

Category: Contact NumberShow more

A Study of Inhaled Ampion in Adults With Respiratory

7 hours ago Clinicaltrials.gov Show details

Ampio Pharmaceuticals. Inc. ClinicalTrials.gov Identifier: NCT04868890 Other Study ID Numbers: AP-019 : First Posted: May 3, 2021 Key Record Dates: Last Update Posted: May 3, 2021 Last Verified: April 2021

Category: Contact NumberShow more

Ampio Pharmaceuticals Strengthens Management Team and

5 hours ago Finance.yahoo.com Show details

-- J. Kevin Buchi and Michael A. Martino join Board of Directors -- Mike Macaluso, CEO of Ampio, realigns his responsibilities with the Ampio executive team and Board while undergoing medical

Category: Contact NumberShow more

Ampio Pharmaceuticals Receives Approval from the Drugs

8 hours ago Dkoding.in Show details

ENGLEWOOD, Colo., Sept. 21, 2021 /PRNewswire/ — Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced regulatory approval from the Drugs Controller General of India (DCGI) of the Central Drugs Standard …

Category: Contact NumberShow more

Ampio Pharmaceuticals, Inc. Announces Second Quarter 2021

8 hours ago Finance.yahoo.com Show details

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are

Category: Contact NumberShow more

Ampio Pharmaceuticals Receives Approval from the Drugs

1 hours ago Finance.yahoo.com Show details

Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced regulatory

Category: Contact NumberShow more

How to buy Ampio Pharmaceuticals stock (NYSE MKT: AMPE

4 hours ago Finder.com Show details

Fact checked. Ampio Pharmaceuticals Inc is a biotechnology business based in the US. Ampio Pharmaceuticals shares (AMPE) are listed on the NYSE MKT and all prices are listed in US Dollars. Ampio Pharmaceuticals employs 18 staff and has a market cap (total outstanding shares value) of 0.00.

Category: Contact NumberShow more

Study of Intravenous Ampion in Adult COVID19 Patients

7 hours ago Clinicaltrials.gov Show details

Ampio Pharmaceuticals. Inc. ClinicalTrials.gov Identifier: NCT04839965 Other Study ID Numbers: AP-017 : First Posted: April 9, 2021 Key Record Dates: Last Update Posted: May 12, 2021 Last Verified: May 2021

Category: Contact NumberShow more

SRO List Food and Drug Administration

3 hours ago Accessdata.fda.gov Show details

SRO List. You can search the list by entering the DUNS NUMBER, BUSINESS NAME, or TICKER SYMBOL in the search criteria. The SRO list is a comprehensive and important resource to check regularly, however, it is not definitive. There are some situations where a financial interest may constitute a prohibited financial interest in an SRO, even if it

Category: Contact NumberShow more

Ampio Pharmaceuticals Inc. (AMEX:AMPE) gain 3.14% – Is It

5 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 196.18 million. AMPE does have institutional investors; and they hold 25.60% of the stock. Ampio Pharmaceuticals Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares.

Category: Contact NumberShow more

Ampio Pharmaceuticals Inc (AMPE) Stock Price & News

4 hours ago Google.com Show details

Ampio (AMPE) gains 3.70% to Close at $1.40 on August 19. InvestorsObserver. 41 minutes ago. Ampio Pharmaceuticals Inc (AMPE) is lower by -4.11% …

Category: Contact NumberShow more

Ampio Pharmaceuticals Inc. (AMPE) upgraded Issued by Wall

4 hours ago Newsheater.com Show details

Ampio Pharmaceuticals Inc. (AMEX:AMPE) went up by 1.80% from its latest closing price compared to the recent 1-year high of $2.98. The company’s stock price has collected 4.94% of gains in the last five trading sessions. Press Release reported on 10/13/21 that Ampio Pharmaceuticals Strengthens Man

Category: Contact NumberShow more

Ampio Provides Update on AP013 Phase III Clinical Trial

1 hours ago Biospace.com Show details

877-901-1999Ampio Annual Meeting & Broadcast: On Saturday, December 14, 2019 at 9:00 AM MT, Ampio will be holding their annual meeting, which will be accessible to all investors calling in at: U.S./ Canada toll-free number: 877-901-1999 U.S. Local number: +1 267-930-4000 Participant Passcode: 853-458-357

Category: Contact NumberShow more

Study of Nebulized Ampion for the Treatment of Adult COVID

7 hours ago Clinicaltrials.gov Show details

Ampio Pharmaceuticals. Inc. ClinicalTrials.gov Identifier: NCT04606784 Other Study ID Numbers: AP-014 : First Posted: October 28, 2020 Key Record Dates: Last Update Posted: March 24, 2021 Last Verified: March 2021

Category: Contact NumberShow more

Bullish Prospects For Ampio Pharmaceuticals Inc. (AMEX

1 hours ago Stocksregister.com Show details

Ampio Pharmaceuticals Inc. (AMEX:AMPE) price on Friday, October 08, fall -1.85% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.59. A look at the stock’s price movement, the close in the last trading session was $1.62, moving within a range at $

Category: Contact NumberShow more

ERIC HARR, BRYAN HARR, Plaintiffs, AMPIO …

3 hours ago Strategicclaims.net Show details

866-274-4004Please do not contact the Court regarding this Notice. All inquiries concerning this Notice, the Proof of Claim Form, or any other questions by Settlement Class Members should be directed to: Ampio Pharmaceuticals, Inc. Litigation c/o Strategic Claims Services P.O. Box 230 600 N. Jackson Street, Ste. 3 Media, Pennsylvania 19063 Tel: 866-274-4004

Category: Contact NumberShow more

Research Shows Ampion™ Gene Regulation Mimics the Anti

3 hours ago Finance.yahoo.com Show details

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the development of Ampion, our product candidate, to treat prevalent inflammatory conditions for which there are

Category: Contact NumberShow more

IND granted to Ampion as COVID19 treatment after Phase I

1 hours ago Europeanpharmaceuticalreview.com Show details

The US Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) and clinical trial application from Ampio Pharmaceuticals to study Ampion TM as an inhalation therapy for respiratory distress due to COVID-19 infection.. Expanding on the recently successful Phase I trial that administered Ampion intravenously to COVID-19 patients, …

Category: Contact NumberShow more

AMPE Stock Price and Chart — AMEX:AMPE — TradingView

6 hours ago Tradingview.com Show details

Ampio Pharmaceuticals exists for over 10 years now. The science behind its leading drug is solid. There were many trials - in none any safety concern rose. Most promising indication is OAK and arthritis in general. Phase-3 results are due to late September. In the last confernece management had clearly stated this timeline.

Category: Contact NumberShow more

Ampio Pharmaceuticals : Receives Approval from the Drugs

8 hours ago Marketscreener.com Show details

ENGLEWOOD, CO, September 21, 2021 - Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced regulatory approval from the Drugs Controller General of India (DCGI) of the Central Drugs Standard Control …

Category: Contact NumberShow more

Ampio Pharmaceuticals : Details Early Positive Results for

Just Now Marketscreener.com Show details

ENGLEWOOD - Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, recently revealed preliminary positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a …

Category: Contact NumberShow more

Ampio Pharmaceuticals : Strengthens Management Team and

3 hours ago Marketscreener.com Show details

ENGLEWOOD, CO, October 13, 2021 - Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced the appointments of Howard Levy, M.B.B.Ch., Ph.D., M.M.M., as Chief Medical Officer (CMO) and J. Kevin Buchi and Michael Martino to the Ampio Pharmaceuticals

Category: Contact NumberShow more

Is Ampio Stock high risk? (NYSEMKT:AMPE) Macroaxis

3 hours ago Macroaxis.com Show details

We consider Ampio Pharmaceuticals dangerous. Ampio Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0265, which signifies that the company had 0.0265% of return per unit of risk over the last 3 months. Our standpoint towards foreseeing the volatility of a stock is to use all available market data together with stock-specific technical indicators that cannot be …

Category: Contact NumberShow more

Statement of Changes in Beneficial Ownership (4)

2 hours ago Ih.advfn.com Show details

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date: 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s

Category: Contact NumberShow more

AMPE News Today (Ampio Pharmaceuticals) MarketBeat

7 hours ago Marketbeat.com Show details

Ampio Pharmaceuticals is Building on its Progress in Tackling Osteoarthritis and COVID-19 Respiratory Issues markets.businessinsider.com - April 1 at 12:29 PM: Ampio Pharmaceuticals to Present at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress finance.yahoo.com - March 29 at 9:32 AM: AMPE Apr 2021 1.500 call

Category: Contact NumberShow more

AMPIO Announces Ampion™ STRIDE Study Results

9 hours ago Prnewswire.com Show details

Ampio Pharmaceuticals launched the Phase III program for Ampion TM – a low molecular weight filtrate of an FDA approved biologic – to treat pain due to osteoarthritis (OA) of the knee. Each

Category: Contact NumberShow more

Ampio Provides Update on AP013 Phase III Clinical Trial

2 hours ago Nasdaq.com Show details

Ampio Annual Meeting & Broadcast: On Saturday, December 14, 2019 at 9:00 AM MT, Ampio will be holding their annual meeting, which will be accessible to all investors calling in at:U.S./ Canada

Category: Contact NumberShow more

Aytu Biopharma Inc (AYTU : NASDAQ) Stock Price & News

8 hours ago Google.com Show details

Ampio Pharmaceuticals Inc. $1.69 AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm. A valuation method that multiplies the price of a company's stock by the total number

Category: Contact NumberShow more

Ampio Pharmaceuticals financials 2021 AMPE Macroaxis

3 hours ago Macroaxis.com Show details

The data published in Ampio Pharmaceuticals' official financial statements usually reflect Ampio Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive …

Category: Contact NumberShow more

Small Cap Biotech Playing Catch Up with Industry Leaders

5 hours ago Healthrapid.us Show details

Small Cap Biotech Playing Catch Up with Industry Leaders. By Dennis Carey on August 24, 2021. This year, Small Cap Biotech firms have lagged behind their larger competitors, who have been able to serve the globe with Covid-19 shots and therapies. Pfizer Inc. soared to new highs after the White House announced fresh recommendations on booster

Category: Tech SupportShow more

Ampio's Phase I Study For Inhaled Ampion Advances To

8 hours ago Stocktitan.net Show details

Do NOT follow this link! December 2, 2020 - 9:15 am. ENGLEWOOD, Colo., Dec. 2, 2020-- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that its AP-014 Phase I inhaled Ampion™ clinical study in COVID …

Category: Contact NumberShow more

What Do Analysts Have To Say About Ampio Pharmaceuticals

2 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 196.18 million. AMPE does have institutional investors; and they hold 27.40% of the stock. Ampio Pharmaceuticals Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 1 new insider purchases involving 22,500 shares.

Category: Contact NumberShow more

Ampio Pharmaceuticals : Reminds Stockholders to Vote

3 hours ago Marketscreener.com Show details

ENGLEWOOD, CO, August 12, 2021 - Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, reminds stockholders to vote on the proposals listed in the Company's proxy …

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is Ampio Pharmaceuticals Inc?

Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of Ampion, our product candidate, to treat prevalent inflammatory conditions for which there are limited treatment options.

Which is the best product candidate for Ampio?

Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee.

What are the uses of ampion in medicine?

Ampion uses the power of the immune response and is in development to treat osteoarthritis, respiratory illness due to COVID-19, and a wide range of other debilitating and life-threatening inflammatory conditions.

What kind of research is Ampio engaged in?

Ampio’s therapeutic product pipeline is the result of more than two decades of research at leading hospital-based research centers. Significant discoveries in both scientific and clinical research have been published in peer-reviewed journals, highlighting the depth of research supporting Ampion’s therapeutic capabilities.

Popular Brands

Amazon
Abbvie
Aia
Asml
Att
Amgen
Apple
Adobe
Aptar
Acc
Adidas
Aak
Aes